Hemosonics’ Quantra System is a novel point-of care (POC) device for the management of high-risk bleeding, especially in cardiothoracic surgery, trauma, orthopaedics and liver transplantation.

This viscoelastic testing system (VET) pioneers the use of ultrasound, delivering results in less than 15 minutes. This fast turnaround-time enables transfusion decisions to be made more quickly  and with greater confidence.

The Quantra QPlus cartridge offers six parameters: clot times with and without heparinase (CT and CTH), clot stiffness (CS) and fibrinogen contribution to clot stiffness (FCS). From these parameters, two unique parameters are automatically calculated. Clot time ratio (CTR) enables faster decisions about whether to administer protamine, while the platelet contribution to clot stiffness (PCS) parameter has been shown to closely correlate with platelet count and function, enabling it to accurately  predict major bleeding [1]. Many clinical guidelines now recommend VET as part of a goal-directed treatment algorithm for dealing with coagulopathic bleeding [2].

For more information, visit: www.hemosonics.com or email contact@hemosonics.com

References: 1. Baryshnikova E, Di Dedda U, Ranucci M. Are viscoelastic tests clinically useful to identify platelet-dependent bleeding in high risk cardiac surgery patients? Anesth Analg. 022;135:1198-1206. doi: https://doi.org/10.1213/ANE.0000000000006231
2. Zlotnik D, Georges A, Lang E, Boucebci K-J, Gautier C-H, Francois A, Gaussem P, Godier A. Assessment of a Quantra-Guided Hemostatic Algorithm in High-Bleeding-Risk Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia 000 (2023) 1 – 8. https://doi.org/10.1053/j.jvca.2023.01.034

Digital issue: Please click here for more information